Table 3.
Binary Endpoint: CRS/ICANS ≥ 3 | OR (95% CI) | p-value |
---|---|---|
EASIX-pre (cutoff >4.67) | 4.32 (1.52–12.67) | 0.006 |
Age (per 10 years) | 0.93 (0.66–1.35) | 0.709 |
Gender male vs. female | 4.56 (1.27–24.81) | 0.018 |
Diagnosis (aggr. B-cell lymphoma vs. other) | 1.07 (0.35–3.68) | 0.905 |
Disease status at lymphodepletion | 1.50 (0.50–4.91) | 0.478 |
EASIX, Endothelial Activation and Stress Index; pre, prior lymphodepletion; log, logarithm; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; OR, odds ratio; 95% CI, 95 percent confidence interval.
Diagnosis patients with aggressive B-cell lymphoma vs. other. Disease status: patients with progressive or refractory disease vs. patients with stable disease or response (complete or partial).